Economic burden of chemotherapy-treated recurrent and/or metastatic squamous cell carcinoma of the head and neck in France: real-world data from the permanent sample of national health insurance beneficiaries

Authors :: Julie Gourmelen
Elodie Torreton
Corinne Emery
Julia Bonastre
Anne-Françoise Gaudin
Antoine Lafuma
François-Emery Cotté
Christophe Le Tourneau
Source :: Journal of Medical Economics. 22:698-705
Publication Year :: 2019
Publisher :: Informa UK Limited, 2019.
Abstract: Aims: Overall survival (OS) of patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) is extremely poor. New therapeutic options emerge but need to establi...

Subjects :: Male
Oncology
medicine.medical_specialty
Databases, Factual
National Health Programs
Cost-Benefit Analysis
medicine.medical_treatment
Sample (statistics)
Sampling Studies
Cohort Studies
Insurance Claim Review
03 medical and health sciences
0302 clinical medicine
Cost of Illness
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Basal cell
Neoplasm Metastasis
Head and neck
Adverse effect
Aged
Retrospective Studies
Aged, 80 and over
Extremely Poor
Chemotherapy
Squamous Cell Carcinoma of Head and Neck
business.industry
030503 health policy & services
Health Policy
Head and neck cancer
Health Care Costs
Middle Aged
medicine.disease
Survival Analysis
stomatognathic diseases
Head and Neck Neoplasms
030220 oncology & carcinogenesis
Female
France
Neoplasm Recurrence, Local
0305 other medical science
business
Real world data

Full Text Access

Tools